Süleyman BÜYÜKBERBER, Umut DEMİRCİ, Meltem BAYKARA, Efnan ALGİN, Gülnihal TUFAN, Burçak CAVNAR, Uğur COŞKUN, Mustafa BENEKLİ

Metastatik gastrik karsinomlu bir olguda metoklopropamid ilişkili nöroleptik malign sendrom

Nöroleptik Malign Sendrom (NMS), hipertermi, müsküler rijidite, şuurdeğişikliği, otonomik disfonksiyon, serum kreatinfosfokinaz (CPK)düzeyinde yükselme ve lökositoz ile karakterize olup; nadir görülen ve fatalseyredebilen bir sendromdur. Metoklopropamid ilişkili NMS nadir fakathayatı tehtid eden bir durumdur. Metoklopropamid ilişkili NMS,metoklopropamidin beyindeki dopamin reseptörlerini bloke etmesi vegüçlü kolinerjik stimulasyon etkisi sonucu ortaya çıkmaktadır. Biz buradametastatik mide kanseri tanısıyla takip edilirken emezis nedeniylemetoklopropamid kullanımı sonrasında NMS gelişen bir olguyu sunuyoruz.

Neuroleptic malignant syndrome associated with metoclopropamide in a patient with metastatic gastric carcinoma

Neuroleptic malignant syndrome (NMS) is a rare syndrome which can be fatal and characterized by hyperthermia, muscular rigidity, changes in consciousness, autonomic dysfunction, increased serum creatinine kinase and leukocytosis. We present a case with metastatic gastric cancer developed neuroleptic malignant syndrome after metoclopropamide treatment.Metoclopropamide-associated neuroleptic malignant syndrome is a rare life-threatening condition. It occurs due to blockade of dopamin receptors by metoclopropamid in brain and high cholinergic stimulation.

PDF

___

1.Robinson MB, Kennett RP, Harding AE, Legg NJ, Clarke B. Neuroleptic malignant syndrome associated with metoclopramide. J Neurol Neurosurg Psychiatry 1985; 48:1304.
2.Jackson N, Doherty J, Coulter S. Neuropsychiatric complications of commonly used palliative care drugs. Postgrad Med J 2008; 84:121-6.
3.Norris B, Angeles V, Eisenstein R, Seale JP. Neuroleptic malignant syndrome with delayed onset of fever following risperidone administration. Ann Pharmacother 2006;40:2260-4.
4.Norgard NB, Stark JE. Olanzapine-associated neuroleptic malignant syndrome. Pharmacotherapy 2006;26:1180-2.
5.Knight ME, Roberts RJ. Phenothiazine and butyrophenone intoxication in children. Pediatr Clin North Am 1986;33:299-309.
6.Bond WS. Detection and management of the neuroleptic malignant syndrome. Clin Pharm 1984;3:302-7.
7.Kawanishi C, Onishi H, Kato D, Yamada T, Onose M, Hirayasu Y. Neuroleptic malignant syndrome in cancer treatment. Palliat Support Care 2005;3:51-3.
8.Spivak B, Gonen N, Mester R, Averbuch E, Adlersberg S, Weizman A. Neuroleptic malignant syndrome associated with abrupt withdrawal of anticholinergic agents. Int Clin Psychopharmacol 1996;11:207-9.
9.Tanii H, Fujita K, Okazaki Y. Neuroleptic malignant syndrome related to a switch to perospirone and anticholinergic withdrawal. Am J Psychiatry 2006;163:547-8.
10.Patterson J F. Neuroleptic malignant syndrome associated with metoclopramide. Southern Medical Journal 1988; 81:674-5.
11.Cassidy T, Bansal SK. Neuroleptic malignant syndrome associated with metoclopramide. British Medical Journal 1988;296:214.
12.Krähenbühl S, Raisin J, Herren T. Malignant neuroleptic syndrome under metoclopramide and neuroleptics in anuria. Schweiz Med Wochenschr 1993; 123:1359-62.
13.Bakri YN, Khan R, Subhi J, Kawi Z. Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy. Gynecol Oncol 1992; 44:189-90.
14.Brower RD, Dreyer CF, Kent TA. Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy related nausea. J Child Neurol 1989;4:230-2.
15.Sanai T, Matsui R, Hirano T, Torichigai S, Yotsueda H, Higashi H, Hirakata H, Iida M. Successful treatment of six patients with neuroleptic malignant syndrome associated with myoglobulinemic acute renal failure. Ren Fail 2006;28:51-5.
16.Kasantikul D, Kanchanatawan B. Neuroleptic malignant syndrome: a review and report of six cases. J Med Assoc Thai 2006;89:2155-60.
17.Jackson N, Doherty J, Coulter S. Neuropsychiatric complications of commonly used palliative care drugs. Postgrad Med J 2008;84:121-6.